While proof of concept for SMN protein increases have been achieved experimentally in fibroblast and other cell lines derived from SMA patients and even in transgenic SMA mouse models for several of these studies, in the majority of cases SMN levels are being quantified using western blot analysis. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.